Information Provided By: 
Fly News Breaks for April 20, 2017
ATRS
Apr 20, 2017 | 16:08 EDT
Raymond James analyst Elliot Wilbur initiated Antares Pharma with a Strong Buy and a $4.30 price target telling investors its business model diversity provides management with multiple value creation levers by playing in the generics arena targeting the $70B U.S. auto-injector and pre-filled syringe market, serving as life-cycle extension partner for branded assets facing end of life crisis or capturing full economic value of self-developed proprietary drugs.
News For ATRS From the Last 2 Days
There are no results for your query ATRS
